Results 21 to 30 of about 53,280 (246)

Cytokine release syndrome in COVID-19 patients, a new scenario for an old concern. The fragile balance between infections and autoimmunity [PDF]

, 2020
On 7 January 2020, researchers isolated and sequenced in China from patients with severe pneumonitis a novel coronavirus, then called SARS-CoV-2, which rapidly spread worldwide, becoming a global health emergency.
Diamanti, A. P., Lagana, B., Pioli, C., Rosado, M. M., Sesti, G.   +4 more
core   +2 more sources

Efficacy and Safety of a Tofacitinib-based Immunosuppressive Regimen After Kidney Transplantation: Results From a Long-term Extension Trial

Transplantation Direct, 2018
Background. Tofacitinib is an oral Janus kinase inhibitor. This open-label, long-term extension (LTE) study (NCT00658359) evaluated long-term tofacitinib treatment in stable kidney transplant recipients (n = 178) posttransplant. Methods.
Stephan Busque, MD, MSc, FRCSC, Flavio G. Vincenti, MD, Helio Tedesco Silva, MD, Philip J. O’Connell, MD, Atsushi Yoshida, MD, John J. Friedewald, MD, Steven M. Steinberg, MD, Klemens Budde, MD, Emine N. Broeders, MD, Yon Su Kim, MD, Carolyn M. Hahn, BA, Huihua Li, MS, Gary Chan, PharmD   +12 more
doaj   +1 more source

Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. [PDF]

, 2018
The myeloma bone marrow microenvironment promotes proliferation of malignant plasma cells and resistance to therapy. Activation of JAK/STAT signaling is thought to be a central component of these microenvironment-induced phenotypes.
Aftab, Blake T, Ferguson, Ian D, Hann, Byron C, Lam, Christine, Lin, Yu-Hsiu T, Liu, Hui, Liu, Jun O, Mariano, Margarette C, Mitsiades, Constantine S, Murnane, Megan, Smith, Geoffrey A, Taunton, Jack, Wiita, Arun P, Wong, Sandy W   +13 more
core   +2 more sources

Tofacitinib Represses the Janus Kinase-Signal Transducer and Activators of Transcription Signalling Pathway in Keratinocytes

Acta Dermato-Venereologica, 2018
Tofacitinib is a Janus kinase (JAK) inhibitor, which has shown efficacy in treating psoriasis. The mode of action of tofacitinib is not completely understood but it has been thought to be mediated by the inhibition of CD4+ T-cell activation.
Ankit Srivastava, Mona Ståhle, Andor Pivarcsi, Enikö Sonkoly   +3 more
doaj   +1 more source

Pharmacokinetic Drug Interaction between Tofacitinib and Voriconazole in Rats

Pharmaceutics, 2021
Fungal infections are prevalent in patients with immune diseases. Voriconazole, a triazole antifungal drug, inhibits the cytochromes CYP3A4 and CYP2C, and tofacitinib, a Janus kinase inhibitor for the treatment of rheumatoid arthritis, is metabolized by ...
Ji-Sang Lee, Hyo-Sung Kim, Yong-Seob Jung, Hyeon-Gyeom Choi, So-Hee Kim   +4 more
doaj   +1 more source

JAK3 as an emerging target for topical treatment of inflammatory skin diseases [PDF]

, 2016
The recent interest and elucidation of the JAK/STAT signaling pathway created new targets for the treatment of inflammatory skin diseases (ISDs). JAK inhibitors in oral and topical formulations have shown beneficial results in psoriasis and alopecia ...
Alves de Medeiros, Ana, De Schepper, Sofie, Desmet, Eline, Lambert, Jo, Speeckaert, Reinhart, Van Gele, Mireille   +5 more
core   +2 more sources

Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies [PDF]

Intestinal Research, 2018
Background/AimsTofacitinib is an oral, small-molecule Janus kinase inhibitor being investigated for ulcerative colitis (UC). In OCTAVE Induction 1 and 2, patients with moderately to severely active UC received placebo or tofacitinib 10 mg twice daily ...
Satoshi Motoya, Mamoru Watanabe, Hyo Jong Kim, Young Ho Kim, Dong Soo Han, Hirotoshi Yuasa, Junichi Tabira, Naoki Isogawa, Shoko Arai, Isao Kawaguchi, Toshifumi Hibi   +10 more
doaj   +1 more source

Future therapeutic targets in rheumatoid arthritis? [PDF]

, 2017
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by persistent joint inflammation. Without adequate treatment, patients with RA will develop joint deformity and progressive functional impairment.
A Balanescu, A Bilancio, A Del Prete, A Maas, AB Avci, AB Satterthwaite, AD Cook, AG Semb, AJ Fleetwood, AJ Fleetwood, AJ Mohamed, AL Bell, AL Cornish, AM Condliffe, AR Pettit, AW Lieshout van, B Ludewig, BF Nashed, BJ Jenkins, BZ Li, C Baerwald, C Meune, C Rommel, C Schindler, C Voigtlander, CA Martin, CJ Heijnen, CM Hilkens, CV Brenol, D Heijde van der, DH Solomon, DJ Rawlings, DL Bellinger, DM Nance, DS Lim, DT Patton, E Banham-Hall, E Clayton, E Feist, E Hirsch, E Martin, E Thomas, EB Lee, EC Tsark, EK Evans, F Berenbaum, F Bussolino, F Ramadani, FA Koopman, FA Koopman, FM Foster, G Hansen, GM Bell, GR Burmester, GR Burmester, H Evrengul, H Wang, Iain B. McInnes, IC Eijk van, IJ Elenkov, IK Campbell, J Askling, J Jang, J Kremer, JA Avina-Zubieta, JA Hamilton, JC Barrientos, JE Park, JM Kremer, JM Waldburger, JS Rawlings, JS Smolen, K Imada, K Okkenhaug, K Okkenhaug, K Okkenhaug, K Pavelka, K Reif, K Shuai, K Thiele, K Yamaoka, KL Winthrop, KP MacDonald, KS Nair, L Conti, L Jansson, L Senolt, L Zhang, L Zou, LC Cantley, LG Schipper, LJ Courtright, LV Borovikova, M Camps, M Dougados, M Field, M Gilliet, M Pesu, M Rosas-Ballina, M Skoberne, M Skoberne, M Soubrier, M Westman, MA Maanen van, MA Maanen van, MA Maanen van, MB Torchinsky, MC Genovese, MC Genovese, MC Genovese, MC Genovese, MC Genovese, MC Genovese, MC Lebre, MC Lebre, MG Roncarolo, MJ Peters, MS Ahmed, MS Thomas, N Krishnamoorthy, N Sato, NJ Gullick, P Geborek, P Norman, P Sujobert, PC Heinrich, PC Taylor, Q Yang, R Fleischmann, R Fleischmann, RA Maldonado, RF Vollenhoven van, RH Straub, RM Buijs, RM Steinman, RM Steinman, S Hayer, S Kleinau, S Mukhopadhyay, S Mukhopadhyay, S Somersan, S Tsukada, SA Provan, ST Jou, T Leizer, T Li, Tommy Tsang Cheung, TR Radstake, WJ Jonge de, WN Khan, Y Ren, Y Xu, YP Goekoop-Ruiterman, Z Li, Z Pan   +154 more
core   +1 more source

Increased risk of herpes zoster with tofacitinib treatment in Korean patients with rheumatoid arthritis: a single-center prospective study

Scientific Reports, 2023
We aimed to determine the risk of herpes zoster (HZ) in Korean rheumatoid arthritis (RA) patients on tofacitinib compared with tumor necrosis factor inhibitor (TNFi) treatment.
Yeo-Jin Song, Soo-Kyung Cho, Hyoungyoung Kim, Hye Won Kim, Eunwoo Nam, Ja-Young Jeon, Hyun-Jeong Yoo, Chan-Bum Choi, Tae-Hwan Kim, Jae-Bum Jun, Sang-Cheol Bae, Dae Hyun Yoo, Yoon-Kyoung Sung   +12 more
doaj   +1 more source

Tofacitinib Blocks Entheseal Lymphocyte Activation and Modulates MSC Adipogenesis, but Does Not Directly Affect Chondro- and Osteogenesis

Immuno, 2021
Entheseal spinal inflammation and new bone formation with progressive ankylosis may occur in ankylosing spondylitis (AS) and psoriatic arthritis (PsA).
Tobias Russell, Hannah Rowe, Charlie Bridgewood, Richard J. Cuthbert, Abdulla Watad, Darren Newton, Elena Jones, Dennis McGonagle   +7 more
doaj   +1 more source